RCUS - Arcus Biosciences, Inc.

QQQ $ 439.55 $ -0.26 (-0.06 %)

DIA $ 390.50 $ 1.74 (0.45 %)

SPY $ 517.10 $ 0.05 (0.01 %)

TLT $ 90.18 $ -0.55 (-0.61 %)

GLD $ 213.58 $ -0.63 (-0.29 %)

Previous Close

$ 15.26

Open

$ 15.30

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 15.07 - $ 15.54

52 Week Range

$ 12.95 - $ 25.47

Volume

503,878

Average Volume

Market Cap

1.32B

Beta (5Y Monthly)

$ 1.40

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-08-2024	03-31-2024	10-Q
2	02-21-2024	12-31-2023	10-K
3	11-07-2023	09-30-2023	10-Q
4	08-07-2023	06-30-2023	10-Q
5	05-09-2023	03-31-2023	10-Q
6	02-28-2023	12-31-2022	10-K
7	11-02-2022	09-30-2022	10-Q
8	08-03-2022	06-30-2022	10-Q
9	05-09-2022	03-31-2022	10-Q
10	02-23-2022	12-31-2021	10-K
11	11-08-2021	09-30-2021	10-Q
12	08-05-2021	06-30-2021	10-Q
13	05-05-2021	03-31-2021	10-Q
14	02-25-2021	12-31-2020	10-K
15	11-05-2020	09-30-2020	10-Q
16	08-06-2020	06-30-2020	10-Q
17	05-05-2020	03-31-2020	10-Q
18	03-05-2020	12-31-2019	10-K
19	11-05-2019	09-30-2019	10-Q
20	08-06-2019	06-30-2019	10-Q
21	05-02-2019	03-31-2019	10-Q
22	03-05-2019	12-31-2018	10-K
23	11-08-2018	09-30-2018	10-Q
24	08-06-2018	06-30-2018	10-Q
25	05-09-2018	03-31-2018	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Arcus Biosciences Q1 2024 GAAP EPS $(0.05)...
05/08/2024 21:31:37

Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.9...

Arcus Biosciences To Present New Data From...
04/24/2024 20:02:16

Updated data from EDGE-Gastric evaluating domvanalimab plus zimberelimab and chemotherapy in upper gastrointestinal (GI) cancer...

Navigating 5 Analyst Ratings For Arcus Bio...
03/25/2024 16:01:09

Truist Securities Reiterates Buy on Arcus ...
03/25/2024 15:54:56

Truist Securities analyst Robyn Karnauskas reiterates Arcus Biosciences (NYSE:RCUS) with a Buy and maintains $50 price target.

Critical Insights From Arcus Biosciences A...
02/22/2024 14:00:14

Wedbush Reiterates Outperform on Arcus Bio...
02/22/2024 13:23:45

Wedbush analyst Robert Driscoll reiterates Arcus Biosciences (NYSE:RCUS) with a Outperform and maintains $30 price target.

Recap: Arcus Biosciences Q4 Earnings
02/21/2024 21:30:18

Arcus Biosciences Q4 2023 GAAP EPS $(1.08)...
02/21/2024 21:28:52

Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0...

Earnings Scheduled For February 21, 2024
02/21/2024 10:09:04

Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on...

Preview: Arcus Biosciences's Earnings
02/20/2024 19:01:04

320m-bet-on-this-healthcare-stock-check-out-these-3-stocks-insiders-are-buying

$320M Bet On This Healthcare Stock? Check ...
02/01/2024 11:09:28

Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades.

Key Takeaways From Arcus Biosciences Analy...
01/30/2024 18:00:19

Wedbush Maintains Outperform on Arcus Bios...
01/30/2024 15:46:26

Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and lowers the price target from $...

Mizuho Maintains Buy on Arcus Biosciences,...
01/30/2024 14:35:55

Mizuho analyst Mara Goldstein maintains Arcus Biosciences (NYSE:RCUS) with a Buy and lowers the price target from $51 to $42.

pharma-giant-gilead-raises-stake-in-cancer-focused-arcus-biosciences-stock-soars

Pharma Giant Gilead Raises Stake In Cancer...
01/30/2024 11:27:56

Arcus Biosciences sees a 17.1% surge as Gilead Sciences amends collaboration, investing $320M at $21.00/share. Accelerate joint...

Gilead and Arcus Announce Amended Collabor...
01/29/2024 22:04:33

– Investment Reinforces Companies' Conviction in TIGIT Pathway and Provides Opportunity to Accelerate the Anti-TIGIT Progra...

Wedbush Reiterates Outperform on Arcus Bio...
01/17/2024 13:24:27

Wedbush analyst Robert Driscoll reiterates Arcus Biosciences (NYSE:RCUS) with a Outperform and maintains $36 price target.

Arcus Biosciences Data From Phase 1b Study...
01/16/2024 22:13:24

Median Overall Survival was 15.7 months for all patients treated with 100 mg quemliclustat-based regimens in the ARC-8 study, w...

Exelixis And Arcus Biosciences Announce Cl...
12/04/2023 13:02:22

– Phase 1b/2 clinical trial expected to begin enrolling patients before year-end 2023 –Exelixis, Inc. (NASDAQ:EXEL) and Arcus B...

Morgan Stanley Maintains Overweight on Arc...
11/13/2023 14:20:52

Morgan Stanley analyst Terence Flynn maintains Arcus Biosciences (NYSE:RCUS) with a Overweight and lowers the price target f...